Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Solid Tumor 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Cetuximab 44Oxaliplatin 39Irinotecan 38Fluorouracil 36Capecitabine 36pembrolizumab 35Leucovorin 35Bevacizumab 35Nivolumab 21Gemcitabine 17regorafenib 13Panitumumab 12IFL protocol 12Folfox protocol 12Cyclophosphamide 12Pemetrexed 11Cisplatin 11tislelizumab 9Paclitaxel 9HMPL-013 9Carboplatin 9130-nm albumin-bound paclitaxel 8durvalumab 7Specimen Handling 7Docetaxel 7trametinib 6Trifluridine 6Ipilimumab 6Drug Therapy 6trifluridine tipiracil drug combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colorectal Neoplasms × LY-2157299 × Clear all
NCT05700656 2024-07-22

Galunisertib Combined With Capecitabine in Advanced CRC With PM

The Netherlands Cancer Institute

Phase 1/2 Recruiting
31 enrolled
GastrointestinalGynecologic

Peritoneal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡